MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $276,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 35.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,022 shares of the company’s stock after purchasing an additional 9,593 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.05% of EyePoint Pharmaceuticals worth $276,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC boosted its stake in shares of EyePoint Pharmaceuticals by 410.4% in the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after purchasing an additional 197,033 shares in the last quarter. abrdn plc acquired a new position in EyePoint Pharmaceuticals during the 4th quarter worth about $1,719,000. Bank of America Corp DE lifted its position in EyePoint Pharmaceuticals by 28.8% during the 4th quarter. Bank of America Corp DE now owns 648,030 shares of the company’s stock worth $4,828,000 after buying an additional 145,065 shares in the last quarter. Raymond James Financial Inc. acquired a new position in EyePoint Pharmaceuticals during the 4th quarter worth about $76,000. Finally, Rhumbline Advisers lifted its position in EyePoint Pharmaceuticals by 16.1% during the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company’s stock worth $667,000 after buying an additional 12,443 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Performance

EyePoint Pharmaceuticals stock opened at $7.21 on Friday. EyePoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $13.99. The company has a market cap of $496.13 million, a PE ratio of -3.61 and a beta of 1.58. The company’s 50-day moving average is $5.86 and its two-hundred day moving average is $6.95.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $24.50 million for the quarter, compared to the consensus estimate of $8.84 million. Research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Chardan Capital reduced their price target on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday. Wall Street Zen upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday, March 14th. Finally, Mizuho reduced their price target on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, May 16th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.38.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.